Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Fungal Disease Awareness Week: Novel antifungals essential to tackle antifungal resistance, says GlobalData

This week (18-22 September) marks Fungal Disease Awareness Week (FDAW) in the US, an annual event in which the Centers for Disease Control and Prevention (CDC) and partners promote activities and outreach that encourage everyone to “Think Fungus”. This often-underestimated health burden is the focus of webinars and interactive events designed to encourage awareness and […]
Read more

CureVac highlights shift to mRNA technology in seasonal influenza vaccine development, says GlobalData

CureVac, in collaboration with GSK, recently announced the advancement of its multivalent, modified mRNA seasonal influenza vaccine candidate into Phase II clinical trials. The interim Phase I results reported positive safety and immunogenicity data, citing observed humoral responses in support of the selection of a vaccine candidate to proceed into Phase II testing. CureVac’s utilization […]
Read more

Major unmet needs plague classification and treatment of myasthenia gravis, says GlobalData

Myasthenia gravis (MG) is an autoimmune and neuromuscular disease characterized by muscle weakness and fatigue. Currently, most of the first-line treatment options are off-label symptomatic therapies, mainly due to their affordability and accessibility, while disease modifying therapies (DMTs) are typically reserved for refractory patients diagnosed with class II-V MG. As a result, major unmet needs […]
Read more

World Sepsis Day 2023: GlobalData highlights promise of new treatments

World Sepsis Day is commemorated on the 13th of September every year to raise awareness about this life-threatening condition, resulting in at least 11 million deaths occurring globally each year. Over 7,000 facilities and organizations around the world are expected to take part in World Sepsis Day, hosting events such as provision of medical education, […]
Read more

BMS mezigdomide and iberdomide poised to transform multiple myeloma treatment landscape, predicts GlobalData

The latest results from a Phase II study highlight the potential of an all-oral combination therapy, featuring Bristol Myers Squibb’s (BMS) cereblon E3 ubiquitin ligase modulator (CELMoD) mezigdomide and dexamethasone in treating patients with triple-class-refractory multiple myeloma (MM). Consequently, the sales of mezigdomide and iberdomide are expected to increase significantly, amid the shifting dynamics within […]
Read more

Crohn’s disease treatment market sees major shift with emergence of biosimilars and next-gen therapies, says GlobalData

There is a transformative shift taking place in the Crohn’s disease (CD) treatment market, challenging AbbVie’s Humira’s long-standing dominance. Adalimumab biosimilars are reshaping the landscape, impacting Humira and competitors like Janssen’s Stelara and Takeda’s Entyvio. With a focus on biologic-exposed CD patients, novel therapies for TNF-refractory individuals are gaining prominence. Advancements in biologics and oral […]
Read more

Humira biosimilar to see $832mn in sales by 2029, forecasts GlobalData

Samsung Bioepis and Organon recently announced positive topline results from a Phase IV clinical trial of SB5, a biosimilar to the reference tumor necrosis factor (TNF) blocker Humira (adalimumab), in patients with moderate-to-severe chronic plaque psoriasis (PsO). The study met its primary endpoint of comparable pharmacokinetic profiles between SB5 and Humira, and showed comparable efficacy, […]
Read more

Commercial impact for some of first drugs released for Medicare price negotiation to be minimal, says GlobalData

The Biden Administration has released its highly anticipated list of 10 drugs selected for Medicare drug price negotiation under the Inflation Reduction Act. The list contains several drugs that may face generic/biosimilar competition before, or very soon after, the negotiated prices start. Therefore, the commercial impact could likely be minimal for some of the drugs, […]
Read more

J&J’s Akeega FDA approval to heat up PARP battle with dual-action treatment for prostate cancer, says GlobalData

The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic castration-resistant prostate cancer (mCRPC). Akeega’s current predicted sales will experience only a slight increase as a result of its narrow label and fierce competition with other recently approved poly(ADP-ribose) polymerase […]
Read more

Opportunity for first indigenous South Korea SGLT-2 and metformin combination therapy to go global, says GlobalData

Daewoong Pharmaceutical recently obtained approvals for its indigenous therapies—sodium–glucose linked transporter-2 (SGLT-2) inhibitor Envlo (enavogliflozin) and its metformin combination drug Envlomet—in South Korea. As prescription trends tilt in favor of SGLT-2 combination therapies globally, the domestic innovator has an opportunity to compete with the established SGLT-2 combination therapies from multinational companies, says GlobalData, a leading […]
Read more

National Immunization Awareness Month provides opportunities to increase influenza vaccination rates, says GlobalData

August is observed as National Immunization Awareness Month (NIAM) in the US to highlight the importance of vaccines in preventing serious illness, complications, and death from infectious diseases. The intention is to educate individuals on the importance of staying up-to-date with routine vaccinations*. During the 2022-2023 influenza season, vaccination was responsible for averting 36.25% of […]
Read more
1 … 29 30 31 32 33 … 108